Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7923181 | 0.77 | KDM4E (0.41) | IKBKBKAT2BKDM4ENOS3NOS1 | |
| SCHEMBL23473992 | 0.74 | KDM4E (0.39) | IKBKBKAT2BKDM4ENOS3NOS1 | |
| SCHEMBL10285457 | 0.69 | HPGD (0.40) | IKBKBKAT2B | |
| SCHEMBL14232405 | 0.68 | IKBKB (0.53) | IKBKBKAT2BKDM4ENOS3NOS1 | |
| SCHEMBL10266973 | 0.67 | CA2 (0.60) | CA2 | |
| SCHEMBL12240485 | 0.66 | NOS3 (0.42) | KDM4ENOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL20321338 | 0.65 | NOS3 (0.41) | NOS3NOS1NOS2SMN1; SMN2CCR1 | |
| SCHEMBL12146866 | 0.64 | CYP3A4 (0.48) | — | |
| SCHEMBL11893012 | 0.64 | CYP1A2 (0.47) | KDM4E | |
| SCHEMBL21016450 | 0.63 | NOS3 (0.39) | NOS3NOS1NOS2SMN1; SMN2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | HGF, HGFAC, MET | IKBKB 167/4885KAT2B 2495/4885KDM4E 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.